TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00123968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: 1x10\^11 per unit vaccine administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: 1x10\^11 per unit vaccine administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: 1x10\^11 per unit vaccine administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: 1x10\^11 per unit vaccine administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: 1x10\^11 per unit vaccine administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: 4 mg administered intramuscularly via injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: 4 mg administered intramuscularly via injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: 4 mg administered intramuscularly via injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-DILUENT013-DIL-VP
Description: Administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-DILUENT013-DIL-VP
Description: Administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-DILUENT013-DIL-VP
Description: Administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-DILUENT013-DIL-VP
Description: Administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-DILUENT013-DIL-VP
Description: Administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-DILUENT013-DIL-VP
Description: Administered intramuscularly via Bioinjector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP placebo
Description: 4 mg administered intramuscularly via injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP placebo
Description: 4 mg administered intramuscularly via injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP placebo
Description: 4 mg administered intramuscularly via injection
Study: NCT01056328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SJM Irrigated Cardiac Ablation System
Description: Irrigated ablation catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved Open Irrigated RF Ablation System
Description: Irrigated ablation catheter
Study: NCT01670149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT03004144

Intervention type: OTHER
Group type: OTHER
Intervention: FLOAT
Study: NCT03662620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
Description: White colored oval three-layer tablet
Study: NCT04889781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Rotatory instruments
Description: Surgical extraction using conventional rotatory instruments to perform osteotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Rotatory instruments
Description: Surgical extraction using conventional rotatory instruments to perform osteotomy
Study: NCT02897193

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Bio's Graft resorbable membrane
Description: Alpha Bio's Graft resorbable collagen membrane
Study: NCT01978912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KTP-001
Description: KTP-001 is one time dose intradiscally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KTP-001
Description: KTP-001 is one time dose intradiscally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KTP-001
Description: KTP-001 is one time dose intradiscally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KTP-001
Description: KTP-001 is one time dose intradiscally.
Study: NCT04895059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose
Description: Form: Tablets Dosage: 20 mg Adminstration way: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
Study: NCT01105403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Description: IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
Study: NCT00075751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT00053846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buspirone hydrochloride
Description: The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02442999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for obstructive sleep apnea

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP - continuous positive airway pressure
Study: NCT03281226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RIPE (2m) and RI (4m)
Description: Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIPE+NAC (2m) and RI (4m)
Description: Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
Study: NCT00044044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 20 mg
Description: Lurasidone 20mg/day tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 40mg
Description: Lurasidone 40mg/day tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg
Description: Lurasidone 80mg/day - 2 40mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol 10mg
Description: Haloperidol 10mg/day tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to Lurasdione and Haloperidol
Study: NCT03925428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molibresib
Description: Given PO
Study: NCT00734409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS) Monitor
Description: BIS monitoring in addition to RASS assessments
Study: NCT02832440

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise programmes
Study: NCT03662620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
Description: White and pink colored oval two-layer tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
Description: White and pink colored oval two-layer tablet
Study: NCT01639586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: respite platform
Description: Impact of the respite platform patient care on health profit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Day care
Description: Impact of the day care on health profit of patient

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No access to a respite structure
Description: Control group without access to a respite structure
Study: NCT02524977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support
Description: Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention Only
Description: Educational conference series

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention Only
Description: Educational conference series
Study: NCT01903525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
Study: NCT02011893

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tonic Stimulation
Description: Prodigy Neurostimulation System with associated components

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst Stimulation
Description: Prodigy Neurostimulation System with associated components
Study: NCT04488107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c
Description: - FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c
Description: - FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: * Letrozole is the latest generation of aromatase inhibitor. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.~* Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years.
Study: NCT01295931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (IC-Green)
Description: 5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
Study: NCT02455141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin plus Cyclophosphamide
Description: Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin plus Cyclophosphamide
Description: Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxanes
Description: Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxanes plus Carboplatin
Description: Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4
Study: NCT00955227

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax seed oil (ALA)
Description: 2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax seed oil (ALA)
Description: 2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
Study: NCT03769467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab IV infusion
Study: NCT02633319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skilful Parenting
Description: Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skilful Parenting
Description: Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agrics
Description: Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agrics
Description: Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
Study: NCT00955227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
Study: NCT03511183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELIRI + bevacizumab
Description: Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XELIRI + bevacizumab
Description: Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX + bevacizumab
Description: Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XELOX + bevacizumab
Description: Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
Study: NCT01723826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
Study: NCT03911375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: Psycho-educational program of stress reduction based on mindfulness. Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.~Each week the theoretical contents necessary to understand the attention development practices proposed in mindfulness-based interventions will be covered. In addition, basic concepts of the psychobiology and psychology of stress and pain are explained. The subjects will have a homework load of approximately 45 minutes per day during the duration of the intervention.
Study: NCT01798082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic organ prolapse decision aid
Study: NCT01773668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated sensor and infusion set.
Study: NCT01852955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
Study: NCT06165107

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02408549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide Tablet
Description: * Active substance: Lacosamide~* Pharmaceutical form: Tablet~* Concentration: 50 mg and 100 mg~* Route of Administration: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide Oral Solution
Description: * Active substance: Lacosamide~* Pharmaceutical form: Oral solution~* Concentration: 10 mg/ml~* Route of Administration: Oral administration
Study: NCT02058342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Play at Home
Description: The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
Study: NCT01220440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate:10mg x 3 for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
Study: NCT03601728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized prehabilitation
Description: The 60-minute education session includes a 30-minute general education on exercise in older adults and a 30-minute instruction on participating in the study intervention (how to work with the personalized circadian-based activity guideline). The education session will be developed and presented by the PI and the certified exercise trainer. The general education session will be designed using materials from Go4Life program from the National Institute on Aging (https://go4life.nia.nig.gov). The personalized circadian-based activity guideline (exercise goal and plan) will be developed by the investigators and the exercise trainer based on the individual's typical daily circadian profile, functional status, preference for exercise.